Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Glen Clova: Fighting autoimmunity with cytokine-carrying virus-like particles

Glasgow-based company betting VLPs can beat biologics on price, dosing and safety for autoimmune and allergic diseases

By Danielle Golovin, Senior Biopharma Analyst, and Richard Guy, Biopharma Analyst
February 21, 2025 8:31 PM UTC

Glen Clova aims to treat autoimmune and allergic diseases by immunizing patients against high levels cytokines. The company believes its approach of attaching cytokine antigens to virus-like particles will beat standard cytokine-targeting biologics on dosing frequency, safety and price.

The biotech, which raised a £4.4 million ($4.9 million) seed round last year, expects to enter IND-enabling studies by year-end...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Glen Clova Scientific Ltd.